Covid-19 roundup: GSK CEO Em­ma Walm­s­ley — some tri­al de­lays, but we’re lim­it­ing the dam­age — so far; Trump plan­ning ‘Warp Speed’ vac­cine plan

All the ma­jor phar­mas are wrestling with the Covid-19 out­break in one way or an­oth­er. For some, like Eli Lil­ly, the ex­ec­u­tive teams have de­layed pa­tient re­cruit­ment on a wide num­ber of tri­als, which will like­ly have a deep im­pact on de­vel­op­ment plans — par­tic­u­lar­ly at the ear­li­er stages.

But over at Glax­o­SmithK­line, the em­pha­sis has been on find­ing ways to keep its op­er­a­tions on track — in­clud­ing R&D. Here’s a lengthy set of re­marks from Em­ma Walm­s­ley’s Q1 re­view, which help en­cap­su­late both the ef­fects of the out­break and their strat­e­gy for deal­ing with it.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER